Effect of Complement on HIV-2 Plasma Antiviral Activity Is Intratype Specific and Potent

Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue Spotlights in the Current Issue JVI About JVI Subscribers Authors Reviewers Advertisers Inquiries from...

Full description

Saved in:
Bibliographic Details
Published inJournal of Virology Vol. 87; no. 1; pp. 273 - 281
Main Authors Özkaya Şahin, Gülşen, Holmgren, Birgitta, Sheik-Khalil, Enas, da Silva, Zacarias, Nielsen, Jens, Nowroozalizadeh, Salma, Månsson, Fredrik, Norrgren, Hans, Aaby, Peter, Fenyö, Eva Maria, Jansson, Marianne
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 01.01.2013
Subjects
Adult
Aged
Antibodies, Neutralizing - blood
Basic Medicine
Cell Line
Complement System Proteins - immunology
Female
HIV Antibodies - blood
HIV-1 - immunology
HIV-2 - immunology
Humans
Immunoglobulin G - blood
Male
Medical and Health Sciences
Medicin och hälsovetenskap
Medicinska och farmaceutiska grundvetenskaper
Microbiology in the Medical Area
Middle Aged
Mikrobiologi inom det medicinska området
Neutralization Tests
Pathogenesis and Immunity
Plasma - immunology
Plasma - virology
Viral Plaque Assay
Online AccessGet full text

Cover

Abstract Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue Spotlights in the Current Issue JVI About JVI Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy JVI RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0022-538X Online ISSN: 1098-5514 Copyright © 2014 by the American Society for Microbiology.   For an alternate route to JVI .asm.org, visit: JVI       
AbstractList Human immunodeficiency virus type 2 (HIV-2)-infected individuals develop immunodeficiency with a considerable delay and transmit the virus at rates lower than HIV-1-infected persons. Conceivably, comparative studies on the immune responsiveness of HIV-1- and HIV-2-infected hosts may help to explain the differences in pathogenesis and transmission between the two types of infection. Previous studies have shown that the neutralizing antibody response is more potent and broader in HIV-2 than in HIV-1 infection. In the present study, we have examined further the function of the humoral immune response and studied the effect of complement on the antiviral activity of plasma from singly HIV-1- or HIV-2-infected individuals, as well as HIV-1/HIV-2 dually infected individuals. The neutralization and antibody-dependent complement-mediated inactivation of HIV-1 and HIV-2 isolates were tested in a plaque reduction assay using U87.CD4.CCR5 cells. The results showed that the addition of complement increased intratype antiviral activities of both HIV-1 and HIV-2 plasma samples, although the complement effect was more pronounced with HIV-2 than HIV-1 plasma. Using an area-under-the-curve (AUC)-based readout, multivariate statistical analysis confirmed that the type of HIV infection was independently associated with the magnitude of the complement effect. The analyses carried out with purified IgG indicated that the complement effect was largely exerted through the classical complement pathway involving IgG in both HIV-1 and HIV-2 infections. In summary, these findings suggest that antibody binding to HIV-2 structures facilitates the efficient use of complement and thereby may be one factor contributing to a strong antiviral activity present in HIV-2 infection.
Human immunodeficiency virus type-2 (HIV-2) infected individuals develop immunodeficiency with a considerable delay and transmit the virus at a lower rate as compared to HIV-1 infected. Conceivably, comparative studies on immune responsiveness of the HIV-1 and HIV-2 infected hosts may help to explain differences in pathogenesis and transmission between the two types of infection. Previous studies have shown that the neutralizing antibody response is more potent and broader in HIV-2 than HIV-1 infection. In the present study we have further examined the function of the humoral immune response and studied the potentiating effect of complement (C') on antiviral activity of plasma from singly HIV-1 or HIV-2 infected, as well as HIV-1/HIV-2 dually infected individuals. Neutralization and antibody-dependent complement-mediated inactivation of HIV-1 and HIV-2 isolates were tested in a plaque reduction assay using U87.CD4-CCR5 cells. Results showed that addition of C' increased intra-type antiviral activity of both HIV-1 and HIV-2 plasma, although the C' effect was more pronounced with HIV-2 than HIV-1 plasma. Using the area-under-curve (AUC)-based readout, multivariate statistical analysis confirmed that type of HIV infection was independently associated with the magnitude of the C' effect. Analysis carried out with purified IgG indicated that the C' effect was largely exerted through the classical C' pathway involving IgG in both HIV-1 and HIV-2 infections. In summary, these findings suggest that antibody binding to HIV-2 structures facilitates efficient use of C', and may thereby be one factor contributing to a strong antiviral activity present in HIV-2 infection.
Human immunodeficiency virus type 2 (HIV-2)-infected individuals develop immunodeficiency with a considerable delay and transmit the virus at rates lower than HIV-1-infected persons. Conceivably, comparative studies on the immune responsiveness of HIV-1- and HIV-2-infected hosts may help to explain the differences in pathogenesis and transmission between the two types of infection. Previous studies have shown that the neutralizing antibody response is more potent and broader in HIV-2 than in HIV-1 infection. In the present study, we have examined further the function of the humoral immune response and studied the effect of complement on the antiviral activity of plasma from singly HIV-1- or HIV-2-infected individuals, as well as HIV-1/HIV-2 dually infected individuals. The neutralization and antibody-dependent complement-mediated inactivation of HIV-1 and HIV-2 isolates were tested in a plaque reduction assay using U87.CD4.CCR5 cells. The results showed that the addition of complement increased intratype antiviral activities of both HIV-1 and HIV-2 plasma samples, although the complement effect was more pronounced with HIV-2 than HIV-1 plasma. Using an area-under-the-curve (AUC)-based readout, multivariate statistical analysis confirmed that the type of HIV infection was independently associated with the magnitude of the complement effect. The analyses carried out with purified IgG indicated that the complement effect was largely exerted through the classical complement pathway involving IgG in both HIV-1 and HIV-2 infections. In summary, these findings suggest that antibody binding to HIV-2 structures facilitates the efficient use of complement and thereby may be one factor contributing to a strong antiviral activity present in HIV-2 infection.Human immunodeficiency virus type 2 (HIV-2)-infected individuals develop immunodeficiency with a considerable delay and transmit the virus at rates lower than HIV-1-infected persons. Conceivably, comparative studies on the immune responsiveness of HIV-1- and HIV-2-infected hosts may help to explain the differences in pathogenesis and transmission between the two types of infection. Previous studies have shown that the neutralizing antibody response is more potent and broader in HIV-2 than in HIV-1 infection. In the present study, we have examined further the function of the humoral immune response and studied the effect of complement on the antiviral activity of plasma from singly HIV-1- or HIV-2-infected individuals, as well as HIV-1/HIV-2 dually infected individuals. The neutralization and antibody-dependent complement-mediated inactivation of HIV-1 and HIV-2 isolates were tested in a plaque reduction assay using U87.CD4.CCR5 cells. The results showed that the addition of complement increased intratype antiviral activities of both HIV-1 and HIV-2 plasma samples, although the complement effect was more pronounced with HIV-2 than HIV-1 plasma. Using an area-under-the-curve (AUC)-based readout, multivariate statistical analysis confirmed that the type of HIV infection was independently associated with the magnitude of the complement effect. The analyses carried out with purified IgG indicated that the complement effect was largely exerted through the classical complement pathway involving IgG in both HIV-1 and HIV-2 infections. In summary, these findings suggest that antibody binding to HIV-2 structures facilitates the efficient use of complement and thereby may be one factor contributing to a strong antiviral activity present in HIV-2 infection.
Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue Spotlights in the Current Issue JVI About JVI Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy JVI RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0022-538X Online ISSN: 1098-5514 Copyright © 2014 by the American Society for Microbiology.   For an alternate route to JVI .asm.org, visit: JVI       
Author Peter Aaby
Marianne Jansson
Jens Nielsen
Gülşen Özkaya Şahin
Fredrik Månsson
Zacarias da Silva
Enas Sheik-Khalil
Birgitta Holmgren
Eva Maria Fenyö
Salma Nowroozalizadeh
Hans Norrgren
Author_xml – sequence: 1
  givenname: Gülşen
  surname: Özkaya Şahin
  fullname: Özkaya Şahin, Gülşen
  organization: Department of Laboratory Medicine, Lund University, Lund, Sweden
– sequence: 2
  givenname: Birgitta
  surname: Holmgren
  fullname: Holmgren, Birgitta
  organization: Department of Laboratory Medicine, Lund University, Lund, Sweden, Department of Laboratory Medicine, Lund University, Malmö, Sweden
– sequence: 3
  givenname: Enas
  surname: Sheik-Khalil
  fullname: Sheik-Khalil, Enas
  organization: Department of Laboratory Medicine, Lund University, Lund, Sweden
– sequence: 4
  givenname: Zacarias
  surname: da Silva
  fullname: da Silva, Zacarias
  organization: Bandim Health Project, INDEPTH Network, Bissau, Guinea-Bissau
– sequence: 5
  givenname: Jens
  surname: Nielsen
  fullname: Nielsen, Jens
  organization: Statens Serum Institute, Copenhagen, Denmark
– sequence: 6
  givenname: Salma
  surname: Nowroozalizadeh
  fullname: Nowroozalizadeh, Salma
  organization: Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
– sequence: 7
  givenname: Fredrik
  surname: Månsson
  fullname: Månsson, Fredrik
  organization: Infectious Diseases Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden
– sequence: 8
  givenname: Hans
  surname: Norrgren
  fullname: Norrgren, Hans
  organization: Department of Clinical Sciences, Division of Infection Medicine, Lund University, Lund, Sweden
– sequence: 9
  givenname: Peter
  surname: Aaby
  fullname: Aaby, Peter
  organization: Bandim Health Project, INDEPTH Network, Bissau, Guinea-Bissau, Statens Serum Institute, Copenhagen, Denmark
– sequence: 10
  givenname: Eva Maria
  surname: Fenyö
  fullname: Fenyö, Eva Maria
  organization: Department of Laboratory Medicine, Lund University, Lund, Sweden
– sequence: 11
  givenname: Marianne
  surname: Jansson
  fullname: Jansson, Marianne
  organization: Department of Laboratory Medicine, Lund University, Lund, Sweden, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23077299$$D View this record in MEDLINE/PubMed
https://lup.lub.lu.se/record/3160590$$DView record from Swedish Publication Index
oai:portal.research.lu.se:publications/ff4f8a23-6ca4-4f67-9971-6842888c6b56$$DView record from Swedish Publication Index
http://kipublications.ki.se/Default.aspx?queryparsed=id:125850169$$DView record from Swedish Publication Index
BookMark eNqNkktvEzEUhS1URNPAjjXykgVT_BqPvUGKokKDIlEJqLqzPB67cfE8OnZS5d_jNKGiSJFYWH6d-52rq3MGTrq-swC8xegcYyI-fr1enCPMGSoweQEmGElRlCVmJ2CCECFFScXNKTiL8Q4hzBhnr8ApoaiqiJQTcHPhnDUJ9g7O-3YItrVdvnXwcnFdEHgVdGw1nHXJb_yoA5yZ3Slt4SLCRZdGnbaDhd8Ha7zzBuqugVd9yozX4KXTIdo3h30Kfn6--DG_LJbfvizms2VhOOKpaFwlZeOakkqmKyorzphztWXY1QbXlOOSIF6hunYIU4QkagSzlKAaU2NQQ6eg2HPjgx3WtRpG3-pxq3rt1eHpVz5ZVVIqpMx6fVQ_9GPSQY02Wj2alQrrXWFWBW908n0XlXPMCU2o4kYzxRyvlJQVVlwwIoQwvC559lge9QjrIa_6wP5P3Kc9LrNa2xi7m3t43vmzn86v1G2_UbSknAqWAe8PgLG_X9uYVOujsSHozvbrqDChEpUCoTJL3_3t9WTyJzFZ8GEvMGMf42jdkwQjtQukyoFUj4HccaeA_CM3Pj3OMnfqw7EiuC9a-dvVgx-tyilUdxuvRKWwIhWlvwEEOO7F
CitedBy_id crossref_primary_10_1016_j_addr_2016_01_013
crossref_primary_10_1016_j_isci_2024_109344
crossref_primary_10_1186_s12981_019_0239_x
crossref_primary_10_1016_j_virol_2017_09_024
crossref_primary_10_3390_ijms23094766
crossref_primary_10_1007_s13365_014_0243_9
crossref_primary_10_1097_QAD_0000000000001223
crossref_primary_10_1097_QAD_0000000000001147
crossref_primary_10_3390_cells11193142
crossref_primary_10_3389_fmicb_2017_01117
crossref_primary_10_1016_j_imlet_2014_10_028
Cites_doi 10.1128/JVI.06155-11
10.1128/JVI.79.5.2823-2830.2005
10.1097/00002030-199813000-00020
10.1007/BF01893018
10.1111/j.1600-0463.2011.02763.x
10.1016/S0092-8674(00)81393-8
10.1002/jemt.1060080103
10.1038/nature04817
10.1016/0042-6822(90)90449-2
10.1097/00002030-200302140-00002
10.1097/00002030-199307000-00001
10.1146/annurev.immunol.24.021605.090557
10.1073/pnas.1120059109
10.1084/jem.183.1.307
10.1099/0022-1317-83-6-1253
10.1590/S0074-02761996000600017
10.1128/JVI.06315-11
10.1002/jmv.1890300411
10.1099/0022-1317-69-10-2455
10.1186/1742-4690-8-16
10.1097/QAD.0b013e328300a33d
10.1016/S0140-6736(89)92281-2
10.1128/JVI.00110-09
10.1016/j.vaccine.2011.11.014
10.1084/jem.169.1.185
10.1016/j.molimm.2004.06.024
10.1111/j.1365-2249.1994.tb07017.x
10.4049/jimmunol.173.8.4775
10.1038/363628a0
10.1016/S0140-6736(89)92321-0
10.1097/QAD.0b013e328011d7ab
10.1038/288338a0
10.1084/jem.182.2.501
10.1371/journal.ppat.1001084
10.1007/BF01487688
10.1128/JVI.06126-11
10.1097/00002030-199310000-00002
10.1001/archinte.160.21.3286
10.1128/JVI.75.11.5230-5239.2001
10.1099/vir.0.81259-0
10.1126/science.150.3695.505
10.1016/j.tim.2008.09.003
10.1016/S0171-2985(11)80158-0
10.1038/nature07159
10.1371/journal.pmed.0030441
10.1097/COH.0b013e32832f0108
10.1099/0022-1317-78-8-1907
10.1097/QAD.0b013e32832cedfb
10.1073/pnas.2634931100
10.1016/j.vaccine.2011.06.085
10.1089/088922202760265623
10.1128/JVI.02789-06
10.1111/j.1365-2796.2007.01819.x
10.1097/00042560-199702010-00002
10.1128/jvi.71.10.7478-7487.1997
10.1371/journal.pone.0010254
10.1128/JVI.73.3.2343-2349.1999
10.4049/jimmunol.157.4.1791
ContentType Journal Article
Copyright Copyright © 2013, American Society for Microbiology. All Rights Reserved. 2013 American Society for Microbiology
Copyright_xml – notice: Copyright © 2013, American Society for Microbiology. All Rights Reserved. 2013 American Society for Microbiology
CorporateAuthor HIV-1 and HIV-2 host interactions
HIV-1 och HIV-2 värd interaktioner
Institutionen för kliniska vetenskaper, Lund
Infektionsmedicin
Lunds universitet
Profile areas and other strong research environments
Department of Laboratory Medicine
Lund University
Sektion III
Institutionen för laboratoriemedicin
Department of Clinical Sciences, Lund
Division of Medical Microbiology
Strategiska forskningsområden (SFO)
EpiHealth: Epidemiology for Health
Faculty of Medicine
Strategic research areas (SRA)
Section III
Infection Medicine (BMC)
Medicinska fakulteten
Avdelningen för medicinsk mikrobiologi
Profilområden och andra starka forskningsmiljöer
CorporateAuthor_xml – name: Faculty of Medicine
– name: Medicinska fakulteten
– name: Strategiska forskningsområden (SFO)
– name: Division of Medical Microbiology
– name: Sektion III
– name: Department of Laboratory Medicine
– name: EpiHealth: Epidemiology for Health
– name: Institutionen för kliniska vetenskaper, Lund
– name: HIV-1 och HIV-2 värd interaktioner
– name: HIV-1 and HIV-2 host interactions
– name: Strategic research areas (SRA)
– name: Lunds universitet
– name: Department of Clinical Sciences, Lund
– name: Profilområden och andra starka forskningsmiljöer
– name: Lund University
– name: Institutionen för laboratoriemedicin
– name: Section III
– name: Profile areas and other strong research environments
– name: Infection Medicine (BMC)
– name: Avdelningen för medicinsk mikrobiologi
– name: Infektionsmedicin
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADTPV
AOWAS
D95
DOI 10.1128/JVI.01640-12
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
SwePub
SwePub Articles
SWEPUB Lunds universitet
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
MEDLINE

CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1098-5514
EndPage 281
ExternalDocumentID oai_swepub_ki_se_533899
oai_portal_research_lu_se_publications_ff4f8a23_6ca4_4f67_9971_6842888c6b56
oai_lup_lub_lu_se_ff4f8a23_6ca4_4f67_9971_6842888c6b56
PMC3536384
23077299
10_1128_JVI_01640_12
jvi_87_1_273
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-~X
.55
.GJ
0R~
18M
29L
2WC
39C
3O-
4.4
41~
53G
5GY
5RE
5VS
6TJ
85S
AAFWJ
AAGFI
AAYJJ
AAYXX
ABPPZ
ACGFO
ACNCT
ADBBV
ADXHL
AENEX
AFFNX
AGVNZ
AI.
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
C1A
CITATION
CS3
D0S
DIK
E3Z
EBS
EJD
F5P
FRP
GX1
H13
HYE
HZ~
IH2
KQ8
MVM
N9A
O9-
OHT
OK1
P2P
RHI
RNS
RPM
RSF
TR2
UPT
VH1
W2D
W8F
WH7
WOQ
X7M
Y6R
YQT
ZGI
ZXP
~02
~KM
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADTPV
AOWAS
D95
ID FETCH-LOGICAL-c606t-df799dfd5394a7397644ffbe41fbc1b361520670bbf0130090d84e320b13cc0d3
ISSN 0022-538X
1098-5514
IngestDate Mon Aug 25 03:37:41 EDT 2025
Thu Aug 21 06:47:40 EDT 2025
Thu Jul 03 04:58:30 EDT 2025
Thu Aug 21 17:51:25 EDT 2025
Fri Jul 11 06:57:56 EDT 2025
Thu Apr 03 06:57:12 EDT 2025
Tue Jul 01 01:02:19 EDT 2025
Thu Apr 24 23:07:20 EDT 2025
Wed May 18 15:26:09 EDT 2016
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c606t-df799dfd5394a7397644ffbe41fbc1b361520670bbf0130090d84e320b13cc0d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://jvi.asm.org/content/jvi/87/1/273.full.pdf
PMID 23077299
PQID 1239058005
PQPubID 23479
PageCount 9
ParticipantIDs pubmed_primary_23077299
crossref_primary_10_1128_JVI_01640_12
swepub_primary_oai_swepub_ki_se_533899
swepub_primary_oai_lup_lub_lu_se_ff4f8a23_6ca4_4f67_9971_6842888c6b56
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3536384
crossref_citationtrail_10_1128_JVI_01640_12
swepub_primary_oai_portal_research_lu_se_publications_ff4f8a23_6ca4_4f67_9971_6842888c6b56
proquest_miscellaneous_1239058005
highwire_asm_jvi_87_1_273
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20130101
2013-01-00
2013-Jan
2013
PublicationDateYYYYMMDD 2013-01-01
PublicationDate_xml – month: 01
  year: 2013
  text: 20130101
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: 1752 N St., N.W., Washington, DC
PublicationTitle Journal of Virology
PublicationTitleAlternate J Virol
PublicationYear 2013
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References e_1_3_2_26_2
e_1_3_2_49_2
e_1_3_2_28_2
e_1_3_2_41_2
e_1_3_2_20_2
e_1_3_2_43_2
e_1_3_2_22_2
e_1_3_2_45_2
e_1_3_2_24_2
e_1_3_2_47_2
e_1_3_2_9_2
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_18_2
e_1_3_2_39_2
e_1_3_2_54_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_52_2
e_1_3_2_5_2
e_1_3_2_12_2
e_1_3_2_33_2
e_1_3_2_58_2
e_1_3_2_3_2
e_1_3_2_14_2
e_1_3_2_35_2
e_1_3_2_56_2
e_1_3_2_50_2
e_1_3_2_27_2
e_1_3_2_48_2
e_1_3_2_40_2
e_1_3_2_21_2
e_1_3_2_42_2
e_1_3_2_23_2
e_1_3_2_44_2
e_1_3_2_25_2
e_1_3_2_46_2
e_1_3_2_61_2
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
e_1_3_2_17_2
e_1_3_2_59_2
e_1_3_2_6_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_53_2
e_1_3_2_32_2
e_1_3_2_51_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_4_2
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_55_2
e_1_3_2_2_2
Sullivan BL (e_1_3_2_57_2) 1996; 157
Poulsen AG (e_1_3_2_29_2) 1993; 6
Jouvin MH (e_1_3_2_60_2) 1987; 1
17301136 - J Virol. 2007 May;81(10):5331-8
6495149 - Springer Semin Immunopathol. 1984;7(2-3):143-62
12556682 - AIDS. 2003 Feb 14;17(3):291-300
16298986 - J Gen Virol. 2005 Dec;86(Pt 12):3385-96
8759769 - J Immunol. 1996 Aug 15;157(4):1791-8
2854553 - J Electron Microsc Tech. 1988 Jan;8(1):3-15
19439467 - J Virol. 2009 Jul;83(14):7337-48
11088091 - Arch Intern Med. 2000 Nov 27;160(21):3286-93
15488605 - Mol Immunol. 2005 Feb;42(2):153-60
22072782 - J Virol. 2012 Jan;86(2):961-71
9311827 - J Virol. 1997 Oct;71(10):7478-87
9764792 - AIDS. 1998 Sep 10;12(13):1707-14
8929542 - Cell. 1996 Nov 15;87(4):745-56
17255738 - AIDS. 2007 Jan 30;21(3):317-24
22219363 - Proc Natl Acad Sci U S A. 2012 Jan 17;109(3):875-80
19521234 - AIDS. 2009 Jul 31;23(12):1575-82
1973445 - J Med Virol. 1990 Apr;30(4):287-93
16551265 - Annu Rev Immunol. 2006;24:739-69
2327077 - Virology. 1990 Apr;175(2):600-4
12230938 - AIDS Res Hum Retroviruses. 2002 Sep 1;18(13):957-67
21401915 - Retrovirology. 2011;8:16
5319759 - Science. 1965 Oct 22;150(3695):505-6
18964021 - Trends Microbiol. 2008 Dec;16(12):588-95
7590866 - Immunobiology. 1995 Jun;193(1):98-113
9266986 - J Gen Virol. 1997 Aug;78 ( Pt 8):1907-11
2909656 - J Exp Med. 1989 Jan 1;169(1):185-96
2564945 - Lancet. 1989 Apr 15;1(8642):852-3
16728975 - Nature. 2006 Jun 15;441(7095):847-52
18668044 - Nature. 2008 Sep 4;455(7209):109-13
15470016 - J Immunol. 2004 Oct 15;173(8):4775-8
17598812 - J Intern Med. 2007 Jul;262(1):5-25
8267903 - AIDS. 1993 Oct;7(10):1307-13
2564911 - Lancet. 1989 Apr 15;1(8642):827-31
7689323 - AIDS. 1993 Jul;7(7):903-10
22031948 - J Virol. 2012 Jan;86(2):947-60
21718747 - Vaccine. 2011 Aug 26;29(37):6191-218
8510754 - Nature. 1993 Jun 17;363(6430):628-30
17121450 - PLoS Med. 2006 Nov;3(11):e441
9283657 - Mem Inst Oswaldo Cruz. 1996 Nov-Dec;91(6):745-6
6776418 - Nature. 1980 Nov 27;288(5789):338-44
22072758 - J Virol. 2012 Jan;86(2):930-46
14668432 - Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15812-7
20824092 - PLoS Pathog. 2010;6(9):e1001084
21749448 - APMIS. 2011 Aug;119(8):487-97
3401118 - Arch Virol. 1988;100(3-4):255-66
9052718 - J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Feb 1;14(2):102-9
7543140 - J Exp Med. 1995 Aug 1;182(2):501-9
8551237 - J Exp Med. 1996 Jan 1;183(1):307-10
8315578 - J Acquir Immune Defic Syndr. 1993 Aug;6(8):941-8
22100891 - Vaccine. 2012 Jun 19;30(29):4310-5
2459300 - J Gen Virol. 1988 Oct;69 ( Pt 10):2455-69
20048703 - Curr Opin HIV AIDS. 2009 Sep;4(5):394-9
18525265 - AIDS. 2008 Jun 19;22(10):1195-202
20421997 - PLoS One. 2010;5(4):e10254
12029140 - J Gen Virol. 2002 Jun;83(Pt 6):1253-65
9971817 - J Virol. 1999 Mar;73(3):2343-9
7907957 - Clin Exp Immunol. 1994 Mar;95(3):450-4
2966632 - AIDS. 1987 Jul;1(2):89-94
15709001 - J Virol. 2005 Mar;79(5):2823-30
11333905 - J Virol. 2001 Jun;75(11):5230-9
References_xml – ident: e_1_3_2_9_2
  doi: 10.1128/JVI.06155-11
– ident: e_1_3_2_15_2
  doi: 10.1128/JVI.79.5.2823-2830.2005
– ident: e_1_3_2_28_2
  doi: 10.1097/00002030-199813000-00020
– ident: e_1_3_2_51_2
  doi: 10.1007/BF01893018
– ident: e_1_3_2_31_2
  doi: 10.1111/j.1600-0463.2011.02763.x
– ident: e_1_3_2_12_2
  doi: 10.1016/S0092-8674(00)81393-8
– ident: e_1_3_2_44_2
  doi: 10.1002/jemt.1060080103
– ident: e_1_3_2_48_2
  doi: 10.1038/nature04817
– ident: e_1_3_2_59_2
  doi: 10.1016/0042-6822(90)90449-2
– ident: e_1_3_2_13_2
  doi: 10.1097/00002030-200302140-00002
– ident: e_1_3_2_26_2
  doi: 10.1097/00002030-199307000-00001
– ident: e_1_3_2_49_2
  doi: 10.1146/annurev.immunol.24.021605.090557
– ident: e_1_3_2_42_2
  doi: 10.1073/pnas.1120059109
– ident: e_1_3_2_55_2
  doi: 10.1084/jem.183.1.307
– ident: e_1_3_2_6_2
  doi: 10.1099/0022-1317-83-6-1253
– ident: e_1_3_2_33_2
  doi: 10.1590/S0074-02761996000600017
– ident: e_1_3_2_10_2
  doi: 10.1128/JVI.06315-11
– ident: e_1_3_2_25_2
  doi: 10.1002/jmv.1890300411
– ident: e_1_3_2_43_2
  doi: 10.1099/0022-1317-69-10-2455
– ident: e_1_3_2_24_2
  doi: 10.1186/1742-4690-8-16
– ident: e_1_3_2_27_2
  doi: 10.1097/QAD.0b013e328300a33d
– ident: e_1_3_2_30_2
  doi: 10.1016/S0140-6736(89)92281-2
– ident: e_1_3_2_38_2
  doi: 10.1128/JVI.00110-09
– ident: e_1_3_2_3_2
  doi: 10.1016/j.vaccine.2011.11.014
– ident: e_1_3_2_19_2
  doi: 10.1084/jem.169.1.185
– volume: 1
  start-page: 89
  year: 1987
  ident: e_1_3_2_60_2
  article-title: Decreased expression of the C3b/C4b complement receptor (CR1) in AIDS and AIDS-related syndromes correlates with clinical subpopulations of patients with HIV infection
  publication-title: AIDS
– ident: e_1_3_2_23_2
  doi: 10.1016/j.molimm.2004.06.024
– ident: e_1_3_2_61_2
  doi: 10.1111/j.1365-2249.1994.tb07017.x
– ident: e_1_3_2_58_2
  doi: 10.4049/jimmunol.173.8.4775
– ident: e_1_3_2_40_2
  doi: 10.1038/363628a0
– ident: e_1_3_2_32_2
  doi: 10.1016/S0140-6736(89)92321-0
– ident: e_1_3_2_5_2
  doi: 10.1097/QAD.0b013e328011d7ab
– ident: e_1_3_2_41_2
  doi: 10.1038/288338a0
– ident: e_1_3_2_54_2
  doi: 10.1084/jem.182.2.501
– ident: e_1_3_2_36_2
  doi: 10.1371/journal.ppat.1001084
– ident: e_1_3_2_46_2
  doi: 10.1007/BF01487688
– ident: e_1_3_2_8_2
  doi: 10.1128/JVI.06126-11
– ident: e_1_3_2_20_2
  doi: 10.1097/00002030-199310000-00002
– ident: e_1_3_2_7_2
  doi: 10.1001/archinte.160.21.3286
– ident: e_1_3_2_52_2
  doi: 10.1128/JVI.75.11.5230-5239.2001
– ident: e_1_3_2_11_2
  doi: 10.1099/vir.0.81259-0
– ident: e_1_3_2_50_2
  doi: 10.1126/science.150.3695.505
– ident: e_1_3_2_4_2
  doi: 10.1016/j.tim.2008.09.003
– ident: e_1_3_2_21_2
  doi: 10.1016/S0171-2985(11)80158-0
– ident: e_1_3_2_45_2
  doi: 10.1038/nature07159
– ident: e_1_3_2_17_2
  doi: 10.1371/journal.pmed.0030441
– ident: e_1_3_2_22_2
  doi: 10.1097/COH.0b013e32832f0108
– ident: e_1_3_2_56_2
  doi: 10.1099/0022-1317-78-8-1907
– ident: e_1_3_2_14_2
  doi: 10.1097/QAD.0b013e32832cedfb
– ident: e_1_3_2_47_2
  doi: 10.1073/pnas.2634931100
– ident: e_1_3_2_2_2
  doi: 10.1016/j.vaccine.2011.06.085
– ident: e_1_3_2_37_2
  doi: 10.1089/088922202760265623
– ident: e_1_3_2_53_2
  doi: 10.1128/JVI.02789-06
– ident: e_1_3_2_16_2
  doi: 10.1111/j.1365-2796.2007.01819.x
– ident: e_1_3_2_18_2
  doi: 10.1097/00042560-199702010-00002
– ident: e_1_3_2_34_2
  doi: 10.1128/jvi.71.10.7478-7487.1997
– ident: e_1_3_2_39_2
  doi: 10.1371/journal.pone.0010254
– ident: e_1_3_2_35_2
  doi: 10.1128/JVI.73.3.2343-2349.1999
– volume: 157
  start-page: 1791
  year: 1996
  ident: e_1_3_2_57_2
  article-title: Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.157.4.1791
– volume: 6
  start-page: 941
  year: 1993
  ident: e_1_3_2_29_2
  article-title: HIV-2 infection in Bissau, West Africa, 1987–1989: incidence, prevalences, and routes of transmission
  publication-title: J. Acquir. Immune Defic. Syndr.
– reference: 9764792 - AIDS. 1998 Sep 10;12(13):1707-14
– reference: 16551265 - Annu Rev Immunol. 2006;24:739-69
– reference: 6495149 - Springer Semin Immunopathol. 1984;7(2-3):143-62
– reference: 2854553 - J Electron Microsc Tech. 1988 Jan;8(1):3-15
– reference: 9283657 - Mem Inst Oswaldo Cruz. 1996 Nov-Dec;91(6):745-6
– reference: 11088091 - Arch Intern Med. 2000 Nov 27;160(21):3286-93
– reference: 8551237 - J Exp Med. 1996 Jan 1;183(1):307-10
– reference: 8759769 - J Immunol. 1996 Aug 15;157(4):1791-8
– reference: 9311827 - J Virol. 1997 Oct;71(10):7478-87
– reference: 8929542 - Cell. 1996 Nov 15;87(4):745-56
– reference: 17121450 - PLoS Med. 2006 Nov;3(11):e441
– reference: 20048703 - Curr Opin HIV AIDS. 2009 Sep;4(5):394-9
– reference: 12230938 - AIDS Res Hum Retroviruses. 2002 Sep 1;18(13):957-67
– reference: 2564911 - Lancet. 1989 Apr 15;1(8642):827-31
– reference: 18964021 - Trends Microbiol. 2008 Dec;16(12):588-95
– reference: 22100891 - Vaccine. 2012 Jun 19;30(29):4310-5
– reference: 6776418 - Nature. 1980 Nov 27;288(5789):338-44
– reference: 7590866 - Immunobiology. 1995 Jun;193(1):98-113
– reference: 2909656 - J Exp Med. 1989 Jan 1;169(1):185-96
– reference: 8267903 - AIDS. 1993 Oct;7(10):1307-13
– reference: 9052718 - J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Feb 1;14(2):102-9
– reference: 14668432 - Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15812-7
– reference: 21718747 - Vaccine. 2011 Aug 26;29(37):6191-218
– reference: 2327077 - Virology. 1990 Apr;175(2):600-4
– reference: 7907957 - Clin Exp Immunol. 1994 Mar;95(3):450-4
– reference: 12556682 - AIDS. 2003 Feb 14;17(3):291-300
– reference: 2459300 - J Gen Virol. 1988 Oct;69 ( Pt 10):2455-69
– reference: 3401118 - Arch Virol. 1988;100(3-4):255-66
– reference: 11333905 - J Virol. 2001 Jun;75(11):5230-9
– reference: 19439467 - J Virol. 2009 Jul;83(14):7337-48
– reference: 17301136 - J Virol. 2007 May;81(10):5331-8
– reference: 22219363 - Proc Natl Acad Sci U S A. 2012 Jan 17;109(3):875-80
– reference: 1973445 - J Med Virol. 1990 Apr;30(4):287-93
– reference: 7543140 - J Exp Med. 1995 Aug 1;182(2):501-9
– reference: 15709001 - J Virol. 2005 Mar;79(5):2823-30
– reference: 7689323 - AIDS. 1993 Jul;7(7):903-10
– reference: 5319759 - Science. 1965 Oct 22;150(3695):505-6
– reference: 9266986 - J Gen Virol. 1997 Aug;78 ( Pt 8):1907-11
– reference: 20824092 - PLoS Pathog. 2010;6(9):e1001084
– reference: 22031948 - J Virol. 2012 Jan;86(2):947-60
– reference: 21749448 - APMIS. 2011 Aug;119(8):487-97
– reference: 8315578 - J Acquir Immune Defic Syndr. 1993 Aug;6(8):941-8
– reference: 21401915 - Retrovirology. 2011;8:16
– reference: 22072758 - J Virol. 2012 Jan;86(2):930-46
– reference: 15488605 - Mol Immunol. 2005 Feb;42(2):153-60
– reference: 22072782 - J Virol. 2012 Jan;86(2):961-71
– reference: 18525265 - AIDS. 2008 Jun 19;22(10):1195-202
– reference: 9971817 - J Virol. 1999 Mar;73(3):2343-9
– reference: 17598812 - J Intern Med. 2007 Jul;262(1):5-25
– reference: 2966632 - AIDS. 1987 Jul;1(2):89-94
– reference: 15470016 - J Immunol. 2004 Oct 15;173(8):4775-8
– reference: 17255738 - AIDS. 2007 Jan 30;21(3):317-24
– reference: 2564945 - Lancet. 1989 Apr 15;1(8642):852-3
– reference: 19521234 - AIDS. 2009 Jul 31;23(12):1575-82
– reference: 16298986 - J Gen Virol. 2005 Dec;86(Pt 12):3385-96
– reference: 8510754 - Nature. 1993 Jun 17;363(6430):628-30
– reference: 18668044 - Nature. 2008 Sep 4;455(7209):109-13
– reference: 20421997 - PLoS One. 2010;5(4):e10254
– reference: 16728975 - Nature. 2006 Jun 15;441(7095):847-52
– reference: 12029140 - J Gen Virol. 2002 Jun;83(Pt 6):1253-65
SSID ssj0014464
Score 2.1370838
Snippet Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley...
Human immunodeficiency virus type 2 (HIV-2)-infected individuals develop immunodeficiency with a considerable delay and transmit the virus at rates lower than...
Human immunodeficiency virus type-2 (HIV-2) infected individuals develop immunodeficiency with a considerable delay and transmit the virus at a lower rate as...
SourceID swepub
pubmedcentral
proquest
pubmed
crossref
highwire
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 273
SubjectTerms Adult
Aged
Antibodies, Neutralizing - blood
Basic Medicine
Cell Line
Complement System Proteins - immunology
Female
HIV Antibodies - blood
HIV-1 - immunology
HIV-2 - immunology
Humans
Immunoglobulin G - blood
Male
Medical and Health Sciences
Medicin och hälsovetenskap
Medicinska och farmaceutiska grundvetenskaper
Microbiology in the Medical Area
Middle Aged
Mikrobiologi inom det medicinska området
Neutralization Tests
Pathogenesis and Immunity
Plasma - immunology
Plasma - virology
Viral Plaque Assay
Title Effect of Complement on HIV-2 Plasma Antiviral Activity Is Intratype Specific and Potent
URI http://jvi.asm.org/content/87/1/273.abstract
https://www.ncbi.nlm.nih.gov/pubmed/23077299
https://www.proquest.com/docview/1239058005
https://pubmed.ncbi.nlm.nih.gov/PMC3536384
https://lup.lub.lu.se/record/3160590
oai:portal.research.lu.se:publications/ff4f8a23-6ca4-4f67-9971-6842888c6b56
http://kipublications.ki.se/Default.aspx?queryparsed=id:125850169
Volume 87
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3ra9swEBdZx2Bfxt7zXmiw7Utw59jyQx_Xkq3p2Bj0QegXIctW4yVzSuMU2r9-d5bsxiSDduyDTVDss6P75XSnexHyXkpPxrBOuBmsZi7zdeImqcpBkVNBrMEWS-vYnO8_or0jtj8Ox73eatTSskq31dXGvJJ_4SqMAV8xS_YWnG2JwgB8Bv7CGTgM5xvx2JYexogKjAzPjWO_7O-Njl0f-xEtfkssD1BgJC-wQtlWEaMF7gQC73H_te5Ar23Z1p_zqomEWddYMSVudRMenew8uprKS9k_kBNTjeArju7sworbwg7THk7PjXzbKc5Pi6qS1z29DiZ5MXW_TcAgqLejh6Vs9fwMCBezi1rBPZEK7HrZ2acwCaZWqGLNUtTMVqWuXWZX0WVFqGltsi7afUxX2D8ebWNVMAwpuV7COsWyZ8szOFI4xCIXWjOdSD8QkZJMMB3FgvN4IND_CNa_itIwukPu-mBl-M1mj3VCgaVcByU0r9_kTfjJp9XX6Go0TZXpTRbLeuBtpzxtrdIcPiQPLGfpZwOsR6SXl4_JPdOd9PIJGRt40bmm1_Ci85LW8KIGXrSFF23gRUcL2sKLNvCiAC9q4PWUHH0ZHu7uubYRh6vAvq3cTMecZzoLA85kjBosY1qnORvoVA3SALRi7ALgpalGR7jHvSxheeB76SBQysuCZ2SrnJf5C0JlAiYC90AMxB6LVZhEWimdJ1jUiHGWOaTfTKZQtko9NkuZidpa9RMBUy_qqRcD3yEf2qvPTHWWv1znNHwRMDfi10UhklgMBIDNIe8aRgkQregvk2U-Xy7gvoB7IVhUoUOeG8a1T8H8CbBLuUPiDkvbCxCJ3W_KYlKXbw_CABY95pChYX7nltuD1yEnG-gY413YimETS-9sxRVwQ-IfNxC3Q9MCaYK9mHD-8j_9mlfkvl83nMFNztdkqzpf5m9A7a_St_Wf8w-VXwTO
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+Complement+on+HIV-2+Plasma+Antiviral+Activity+Is+Intratype+Specific+and+Potent&rft.jtitle=Journal+of+virology&rft.au=%C3%96zkaya+Sahin%2C+G%C3%BClsen&rft.au=Holmgren%2C+Birgitta+G&rft.au=Sheik-Khalil%2C+Enas&rft.au=da+Silva%2C+Zacarias&rft.date=2013&rft.issn=1098-5514&rft.volume=87&rft.issue=1&rft.spage=273&rft_id=info:doi/10.1128%2FJVI.01640-12&rft.externalDocID=oai_lup_lub_lu_se_ff4f8a23_6ca4_4f67_9971_6842888c6b56
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon